NCT06345495View on ClinicalTrials.gov

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2029

Conditions

SplenomegalyMyelofibrosis

Interventions

DRUG

Ruxolitinib

Given by PO

PROCEDURE

Allogeneic Stem Cell Transplantation

Given by Transplant

DRUG

Levetiracetam

Given by PO

DRUG

Eltrombopag

Given by PO

DRUG

Busulfan

Given by IV

DRUG

Romiplostim

Given by IV

DRUG

Fludarabine phosphate

Given by IV

DRUG

Cyclophosphamide

Given by IV

DRUG

Mesna

Given by IV

DRUG

Tacrolimus

Given by IV or PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER